[1]
Abel G,Thompson L, "I don't want to look like an AIDS victim": A New Zealand case study of facial lipoatrophy. Health & social care in the community. 2018 Jan
[PubMed PMID: 28557181]
Level 3 (low-level) evidence
[2]
Verolet CM,Delhumeau-Cartier C,Sartori M,Toma S,Zawadynski S,Becker M,Bernasconi E,Trellu LT,Calmy A, Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders. AIDS research and therapy. 2015
[PubMed PMID: 26097493]
Level 2 (mid-level) evidence
[3]
Beraldo RA,Santos APD,Guimarães MP,Vassimon HS,Paula FJA,Machado DRL,Foss-Freitas MC,Navarro AM, Body fat redistribution and changes in lipid and glucose metabolism in people living with HIV/AIDS. Revista brasileira de epidemiologia = Brazilian journal of epidemiology. 2017 Jul-Sep
[PubMed PMID: 29160443]
[4]
Wohl DA,McComsey G,Tebas P,Brown TT,Glesby MJ,Reeds D,Shikuma C,Mulligan K,Dube M,Wininger D,Huang J,Revuelta M,Currier J,Swindells S,Fichtenbaum C,Basar M,Tungsiripat M,Meyer W,Weihe J,Wanke C, Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006 Sep 1
[PubMed PMID: 16886161]
[5]
Martin A,Smith DE,Carr A,Ringland C,Amin J,Emery S,Hoy J,Workman C,Doong N,Freund J,Cooper DA, Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS (London, England). 2004 Apr 30
[PubMed PMID: 15096806]
[6]
Podzamczer D,Ferrer E,Sanchez P,Gatell JM,Crespo M,Fisac C,Lonca M,Sanz J,Niubo J,Veloso S,Llibre JM,Barrufet P,Ribas MA,Merino E,Ribera E,Martínez-Lacasa J,Alonso C,Aranda M,Pulido F,Berenguer J,Delegido A,Pedreira JD,Lérida A,Rubio R,del Río L,ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team., Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. Journal of acquired immune deficiency syndromes (1999). 2007 Feb 1
[PubMed PMID: 17106274]
Level 1 (high-level) evidence
[7]
Gallant JE,DeJesus E,Arribas JR,Pozniak AL,Gazzard B,Campo RE,Lu B,McColl D,Chuck S,Enejosa J,Toole JJ,Cheng AK,Study 934 Group., Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. The New England journal of medicine. 2006 Jan 19
[PubMed PMID: 16421366]
[8]
Dubé MP,Parker RA,Tebas P,Grinspoon SK,Zackin RA,Robbins GK,Roubenoff R,Shafer RW,Wininger DA,Meyer WA 3rd,Snyder SW,Mulligan K, Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (London, England). 2005 Nov 4
[PubMed PMID: 16227788]
Level 1 (high-level) evidence
[9]
McDermott AY,Terrin N,Wanke C,Skinner S,Tchetgen E,Shevitz AH, CD4 cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2005 Dec 1;
[PubMed PMID: 16267741]
[10]
Duong M,Petit JM,Piroth L,Grappin M,Buisson M,Chavanet P,Hillon P,Portier H, Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999). 2001 Jul 1
[PubMed PMID: 11464143]
[11]
Jacobson DL,Knox T,Spiegelman D,Skinner S,Gorbach S,Wanke C, Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2005 Jun 15
[PubMed PMID: 15909274]
[12]
Hadigan C, Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003;
[PubMed PMID: 12942382]
[13]
Hendricks KM,Dong KR,Tang AM,Ding B,Spiegelman D,Woods MN,Wanke CA, High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. The American journal of clinical nutrition. 2003 Oct
[PubMed PMID: 14522738]
[14]
Heath KV,Hogg RS,Chan KJ,Harris M,Montessori V,O'Shaughnessy MV,Montanera JS, Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS (London, England). 2001 Jan 26
[PubMed PMID: 11216932]
[15]
Mallon PW,Miller J,Cooper DA,Carr A, Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (London, England). 2003 May 2
[PubMed PMID: 12700446]
[16]
Fiorenza CG,Chou SH,Mantzoros CS, Lipodystrophy: pathophysiology and advances in treatment. Nature reviews. Endocrinology. 2011 Mar
[PubMed PMID: 21079616]
Level 3 (low-level) evidence
[17]
Glidden DV,Mulligan K,McMahan V,Anderson PL,Guanira J,Chariyalertsak S,Buchbinder SP,Bekker LG,Schechter M,Grinsztejn B,Grant RM, Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Jul 18
[PubMed PMID: 29415175]
[18]
Ranade K,Geese WJ,Noor M,Flint O,Tebas P,Mulligan K,Powderly W,Grinspoon SK,Dube MP, Genetic analysis implicates resistin in HIV lipodystrophy. AIDS (London, England). 2008 Aug 20;
[PubMed PMID: 18670214]
[19]
Zanone Poma B,Riva A,Nasi M,Cicconi P,Broggini V,Lepri AC,Mologni D,Mazzotta F,Monforte AD,Mussini C,Cossarizza A,Galli M,Icona Foundation Study Group., Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS (London, England). 2008 Sep 12
[PubMed PMID: 18753860]
[20]
Srinivasa S,Garcia-Martin R,Torriani M,Fitch KV,Carlson AR,Kahn CR,Grinspoon SK, Altered pattern of circulating miRNAs in HIV lipodystrophy perturbs key adipose differentiation and inflammation pathways. JCI insight. 2021 Sep 22
[PubMed PMID: 34383714]
[22]
Guaraldi G,Fontdevila J,Christensen LH,Orlando G,Stentarelli C,Carli F,Zona S,de Santis G,Pedone A,De Fazio D,Bonucci P,Martínez E, Surgical correction of HIV-associated facial lipoatrophy. AIDS (London, England). 2011 Jan 2
[PubMed PMID: 20975513]
[23]
Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM)., Fat distribution in women with HIV infection. Journal of acquired immune deficiency syndromes (1999). 2006 Aug 15
[PubMed PMID: 16837863]
[24]
Wohl D,Scherzer R,Heymsfield S,Simberkoff M,Sidney S,Bacchetti P,Grunfeld C,FRAM Study Investigators., The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. Journal of acquired immune deficiency syndromes (1999). 2008 May 1
[PubMed PMID: 18360291]
[25]
Moyle GJ,Sabin CA,Cartledge J,Johnson M,Wilkins E,Churchill D,Hay P,Fakoya A,Murphy M,Scullard G,Leen C,Reilly G, A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (London, England). 2006 Oct 24;
[PubMed PMID: 17053350]
Level 2 (mid-level) evidence
[26]
Tebas P,Zhang J,Yarasheski K,Evans S,Fischl MA,Shevitz A,Feinberg J,Collier AC,Shikuma C,Brizz B,Sattler F,AIDS Clinical Trials Group (ACTG)., Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Journal of acquired immune deficiency syndromes (1999). 2007 Jun 1
[PubMed PMID: 17527093]
Level 1 (high-level) evidence
[27]
Fisac C,Fumero E,Crespo M,Roson B,Ferrer E,Virgili N,Ribera E,Gatell JM,Podzamczer D, Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS (London, England). 2005 Jun 10
[PubMed PMID: 15905672]
[28]
Moyle GJ,Andrade-Villanueva J,Girard PM,Antinori A,Salvato P,Bogner JR,Hay P,Santos J,Astier L,Pans M,Balogh A,Biguenet S,ReAL Study Team., A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antiviral therapy. 2012
[PubMed PMID: 22388634]
Level 2 (mid-level) evidence
[29]
Grinspoon S, Use of thiazolidinediones in HIV-infected patients: what have we learned? The Journal of infectious diseases. 2007 Jun 15;
[PubMed PMID: 17492586]
[30]
Slama L,Lanoy E,Valantin MA,Bastard JP,Chermak A,Boutekatjirt A,William-Faltaos D,Billaud E,Molina JM,Capeau J,Costagliola D,Rozenbaum W, Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antiviral therapy. 2008;
[PubMed PMID: 18389900]
Level 1 (high-level) evidence
[31]
Loutfy MR,Raboud JM,Antoniou T,Kovacs C,Shen S,Halpenny R,Ellenor D,Ezekiel D,Zhao A,Beninger F, Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS (London, England). 2007 May 31
[PubMed PMID: 17502725]
[32]
Funk E,Bressler FJ,Brissett AE, Contemporary surgical management of HIV-associated facial lipoatrophy. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2006 Jun
[PubMed PMID: 16730549]
[33]
McComsey GA,Walker UA,Budhathoki CB,Su Z,Currier JS,Kosmiski L,Naini LG,Charles S,Medvik K,Aberg JA,AIDS Clinical Trials Group A5229 Team., Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS (London, England). 2010 Oct 23
[PubMed PMID: 20827170]
[34]
Thöni GJ,Fedou C,Brun JF,Fabre J,Renard E,Reynes J,Varray A,Mercier J, Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes
[PubMed PMID: 12461477]
[35]
Kohli R,Shevitz A,Gorbach S,Wanke C, A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV medicine. 2007 Oct;
[PubMed PMID: 17760733]
Level 1 (high-level) evidence
[36]
Falutz J,Allas S,Blot K,Potvin D,Kotler D,Somero M,Berger D,Brown S,Richmond G,Fessel J,Turner R,Grinspoon S, Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine. 2007 Dec 6
[PubMed PMID: 18057338]
[37]
Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of acquired immune deficiency syndromes (1999). 2010 Mar:53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff. Epub
[PubMed PMID: 20101189]
Level 1 (high-level) evidence
[38]
Pavlidis L,Spyropoulou GA,Demiri E, Comparing Efficacy and Costs of Four Facial Fillers in Human Immunodeficiency Virus-Associated Lipodystrophy: A Clinical Trial. Plastic and reconstructive surgery. 2018 Oct
[PubMed PMID: 30036337]
[39]
Andrade GA,Coltro PS,Barros ME,Müller Neto BF,Lima RV,Farina JA Jr, Gluteal Augmentation With Intramuscular Implants in Patients With Human Immunodeficiency Virus With Lipoatrophy Related to the Use of Antiretroviral Therapy. Annals of plastic surgery. 2017 Nov
[PubMed PMID: 28604545]
[40]
Hausauer AK,Jones DH, Long-Term Correction of Iatrogenic Lipoatrophy With Volumizing Hyaluronic Acid Filler. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2018 Nov
[PubMed PMID: 30359336]
[41]
Lake JE,Stanley TL,Apovian CM,Bhasin S,Brown TT,Capeau J,Currier JS,Dube MP,Falutz J,Grinspoon SK,Guaraldi G,Martinez E,McComsey GA,Sattler FR,Erlandson KM, Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 May 15
[PubMed PMID: 28329372]